The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as “APSAP compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumor, etc.
本发明涉及治疗化合物领域,更具体地涉及以下公式(I)的某些芳基-苯基-磺酰胺基-苯基化合物(统称为“
APSAP化合物”)。本发明还涉及包含这种化合物的制药组合物,以及这种化合物和组合物的使用,无论是体外还是体内,用于治疗炎症和/或关节破坏和/或骨质流失等疾病;过度和/或不适当和/或长时间激活免疫系统介导的疾病;炎症性和自身免疫性疾病,例如类风湿性关节炎、
银屑病、
银屑病性关节炎、慢性阻塞性肺疾病(
COPD)、动脉硬化、炎症性肠病、强直性脊柱炎等;与骨质流失有关的疾病,例如类风湿性关节炎中过度破骨细胞活性、骨质疏松症、与癌症相关的骨病、帕吉特病等;以及癌症,例如血液系统恶性肿瘤、实体肿瘤等。